Spectrum Pharmaceuticals Aktie [WKN: 164623 / ISIN: US84763A1088]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Spectrum Pharmaceuticals IncShs

26.02.19		Ausblick: Spectrum Pharmaceuticals gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
21.02.19		Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results Conference Call (Businesswire)
07.02.19		Spectrum Pharmaceuticals to Present Corporate Update at the Guggenheim Healthcare Talks Idea Forum on February 14 (Businesswire)
17.01.19		Spectrum Pharmaceuticals Sells Marketed Portfolio to Acrotech Biopharma L.L.C. to Focus on New and Innovative Therapies for Cancer Patients (Businesswire)
02.01.19		Spectrum Pharmaceuticals Announces Full Enrollment of the Poziotinib EGFR Cohort for Previously Treated Non-Small Cell Lung Cancer Patients with Exon 20 Insertion Mutations (Businesswire)
27.12.18		Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS® (eflapegrastim) as a Treatment for Chemotherapy-Induced Neutropenia (Businesswire)
20.12.18		Spectrum Pharmaceuticals Continues To Post Steep Loss (RTTNews)
20.12.18		7 Stocks That Made Big Moves After-hours (TLRY, SPPI, ADMA, DBVT...) (RTTNews)
19.12.18		Spectrum Pharmaceuticals Provides Poziotinib Update (Businesswire)
06.12.18		Spectrum Pharmaceuticals Announces Results from the RECOVER Phase 3 Study of ROLONTIS® (eflapegrastim) at the 2018 SABCS Annual Meeting (Businesswire)
03.12.18		Spectrum Pharmaceuticals Announces Positive Results from Phase 2 Trial Evaluating Use of Oral Leucovorin to Potentially Mitigate Mucositis in Patients Treated with FOLOTYN® (pralatrexate) (Businesswire)
30.11.18		Spectrum Pharmaceuticals Highlights Three Posters at the 60th Annual Meeting of the American Society of Hematology (Businesswire)
13.11.18		Spectrum Pharmaceuticals Appoints Dr. Jeffrey Vacirca to its Board of Directors (Businesswire)
08.11.18		Spectrum Pharmaceuticals Reports Third Quarter 2018 Pipeline Update and Financial Results (Businesswire)
07.11.18		Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 London Healthcare Conference on November 14 (Businesswire)
07.11.18		Ausblick: Spectrum Pharmaceuticals präsentiert Bilanzzahlen zum jüngsten Jahresviertel (finanzen.net)
01.11.18		Spectrum Pharmaceuticals Announces Third Quarter 2018 Financial Results Teleconference and Webcast (Businesswire)
23.10.18		Spectrum Pharmaceuticals Receives FDA Approval of KHAPZORY™ (levoleucovorin) for injection (Businesswire)
18.10.18		Spectrum Pharmaceuticals Announces Dr. Francois Lebel as Chief Medical Officer (Businesswire)
27.09.18		Spectrum Pharmaceuticals to Present Corporate Update at the 2018 Cantor Global Healthcare Conference on October 2 (Businesswire)
24.09.18		Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients (Businesswire)
22.09.18		Week Ahead In Pharmaceuticals: 10 Stocks To Watch (CKPT, SNDX, ADMP...) (RTTNews)
12.09.18		Spectrum Pharmaceuticals Expands Poziotinib Clinical Trial Into First-Line Therapy and Doses First Patient (Businesswire)
05.09.18		Spectrum Pharmaceuticals Announces Release of Poziotinib Abstract as Part of the IASLC 19th World Conference on Lung Cancer (Businesswire)
30.08.18		Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September (Businesswire)
09.08.18		Spectrum Pharmaceuticals Reports Second Quarter 2018 Financial Results and Pipeline Update (Businesswire)
02.08.18		Spectrum Pharmaceuticals Announces Second Quarter 2018 Financial Results Teleconference and Webcast (Businesswire)
29.06.18		Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS® (eflapegrastim) Data at MASCC 2018 and Announces the Phase 3 RECOVER Study Met the Primary Endpoint (Businesswire)
27.06.18		SPHS Rebounds, ACHV Soars On New Data, PBYI Gains On CHMP Opinion, SPPI Abuzz (RTTNews)
25.06.18		Spectrum Pharmaceuticals to Host Conference Call Highlighting ROLONTIS® (eflapegrastim) Phase 3 ADVANCE Study Data Presented at Multinational Association of Supportive Care in Cancer (MASCC) (Businesswire)
30.05.18		Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 Global Healthcare Conference on June 6th (Businesswire)
16.05.18		Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract (Businesswire)
09.05.18		Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2018 Health Care Conference on May 16th (Businesswire)
03.05.18		Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results and Pipeline Update (Businesswire)
03.05.18		Spectrum Pharmaceuticals Announces Exclusive Licensing Agreement on Certain Methods of Use of Poziotinib with The University of Texas MD Anderson Cancer Center (Businesswire)
01.05.18		Spectrum Pharmaceuticals Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo Fisher Scientific (Businesswire)
30.04.18		Spectrum Pharmaceuticals Announces Corporate Governance Enhancements and Board Changes (Businesswire)
26.04.18		Spectrum Pharmaceuticals Announces First Quarter 2018 Financial Results Teleconference and Webcast (Businesswire)
23.04.18		Spectrum Pharmaceuticals Announces Publication of Poziotinib Data in Nature Medicine (Businesswire)
11.04.18		SPPI Shines On NSCLC Data, TNDM Sales Up 42%, TORC Breathes Easy, VRAY Abuzz (RTTNews)
10.04.18		Spectrum Pharmaceuticals Announces Update of MD Anderson’s Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients (Businesswire)
03.04.18		Spectrum Pharmaceuticals to Present Corporate Update at the H.C. Wainwright Global Life Sciences Conference on April 10th (Businesswire)
07.03.18		Spectrum Pharmaceuticals to Present Corporate Update at the Cowen and Company 38th Annual Health Care Conference on March 13th (Businesswire)
06.03.18		Spectrum Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results and Pipeline Update (Businesswire)
27.02.18		Spectrum Pharmaceuticals Announces Appointment of William L. Ashton to its Board of Directors (Businesswire)
26.02.18		Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results Teleconference and Webcast (Businesswire)
15.02.18		Spectrum Pharmaceuticals to Present Corporate Update at the 2018 RBC Capital Markets Global Healthcare Conference on February 22nd (Businesswire)
06.02.18		Xtandi Prospers, One Down, One To Go For AMAG, There's Reason For CORT's Fall (RTTNews)

Zurück | 1 | 2 | 3 | 4 | Weiter

Newssuche

Meistgelesene Nachrichten

Tesla-CFO schlägt Alarm: Werden Trump-Zölle zur Bedrohung?

Ausblick: Super Micro Computer vermeldet Zahlen zum jüngsten Quartal

Apple überrascht: Neues iPhone SE könnte früher kommen als erwartet

So bewegt Trumps Zollpolitik den Goldpreis und die Newmont Mining- & Barrick Gold-Aktien

Palantir-Aktie nach Kursrally: Lohnt sich jetzt noch ein Einstieg?

Pierer-Mobility-Aktie in Grün: AR-Chef Zöchling könnte als KTM-Investor mitmischen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	12.02.2025 14:32
Kaufwert:	EUR
	Hinzufügen Speichern